Ulcerative Colitis
A chronic inflammatory disease of the colon characterized by periods of flares and remissions. FMT is being studied as a promising method to restore microbiome balance and reduce inflammation.
What is ulcerative colitis?
Ulcerative colitis is a chronic inflammatory bowel disease (IBD) that affects the mucosal lining of the colon.
About the condition
In ulcerative colitis, the immune system mistakenly attacks the cells of the intestinal lining, causing chronic inflammation. The disease usually begins in the rectum and can spread upward through the colon.
Symptoms
- Bloody diarrhea (the primary symptom)
- False urge to defecate (tenesmus)
- Abdominal pain, especially on the left side
- Weight loss, weakness, anemia
- Nighttime bowel movements
Causes and contributing factors
- Genetic predisposition
- Dysregulated immune response
- Gut microbiota imbalance
- Environmental factors
Standard treatment
Conventional therapy includes anti-inflammatory drugs and immunosuppressants, which are not always effective.
In 15–20% of patients, standard therapy is ineffective, and biologic medications lose their effect over time.
Why FMT for ulcerative colitis?
Microbiota imbalance plays a key role in inflammation. FMT can help restore a healthy microbiome.
Dysbiosis
Reduced microbiota diversity
Inflammation
Compromised intestinal barrier function
FMT transplantation
Introduction of healthy microbiota
Recovery
Reduced inflammation, remission
Mechanism of action
Healthy microbiota restores the balance of pro- and anti-inflammatory bacteria, strengthens the intestinal barrier, and modulates the immune response, reducing chronic inflammation.
Advantages of FMT
- Targets the cause, not just symptoms
- Potential for sustained remission
- Minimal side effects
- Alternative when standard therapy fails
Research results
FMT for ulcerative colitis is actively being studied — there is already compelling data from randomized controlled trials.
64.3%
510 Han's United patients, 3 months
4+ RCTs
Randomized controlled trials
510
IBD patients in the Han's United cohort
Lancet
Publications in leading journals
Key studies
- Moayyedi et al., Gastroenterology 2015: One of the first RCTs — FMT more effective than placebo for ulcerative colitis
- Paramsothy et al., Lancet 2017: Multi-donor intensive FMT protocol — significant improvement in active UC
- Han's United (cohort of 15,000 patients): 510 IBD patients — clinical improvement at 3 months in 64.3% (328 patients)
¥28,400 vs $17,500 for VOWST in USA
Free consultation · We respond within 24 hours
Patient story
Experience of treating ulcerative colitis with FMT
"For seven years, I struggled with ulcerative colitis. Flares happened several times a year, and standard therapy was losing its effect. At Han's United, I was prescribed an intensive FMT course. After three months, symptoms decreased significantly. My quality of life changed dramatically — I can plan my life again without constantly thinking about where the nearest restroom is."
Zhang H.
39 years old, Shanghai
* Name changed. Results are individual and may vary.
Related conditions
FMT is also being studied for other GI conditions
Crohn's Disease
Inflammatory bowel disease. Part of the IBD cohort (510 Han's United patients).
IBS
1,940 Han's United patients, 70.6% improvement at 3 months.
Functional GI
8,258 constipation patients — 70.3% improvement. Largest group in the Han's United cohort.
Chronic Diarrhea
1,730 Han's United patients, 81.0% improvement at 3 months and 72.3% at 3 years.
Related Articles
Find out if FMT is right for you
If standard ulcerative colitis therapy is not effective enough, schedule a consultation. A doctor will evaluate your situation and explain the treatment options.
Free consultation · We respond within 24 hours
China, Jiangxi Province, Shangrao City, Guangxin District, West Binjiang Road